DarioHealth Appoints Eric Milledge as Chairman of its Newly Established Scientific Advisory Board
40+ year healthcare career includes serving as Company Group Chairman at LifeScan, Inc., a multi-billion-dollar diabetes franchise previously owned by Johnson & Johnson (JNJ)
Scientific Advisory Board will help develop and execute the Company's strategic roadmap for refining, improving and expanding its digital therapeutics platform
Sep 16, 2020
NEW YORK, Sept. 16, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announces that Eric Milledge has joined DarioHealth as Chairman of the company's newly-established Scientific Advisory Board (SAB).
Eric Milledge has worked in the healthcare field for his entire career, with a focus on pharmaceuticals and medical devices. With more than 34 years at Johnson & Johnson (JNJ) in roles of increasing responsibility, he built a vast network of relationships across the healthcare landscape.
As president of Ortho McNeil Pharmaceutical, Eric led in the licensing and successful introduction of levofloxacin (antibiotic), tramadol (analgesic) and the commercialization of topamax (anticonvulsant), building a multi-billion dollar U.S. pharmaceutical business. Eric also served as Company Group Chairman for Johnson & Johnson Healthcare Systems which oversaw the negotiation and management of JNJ's medical device, diagnostic and pharmaceutical U.S. hospital contracts. Eric also served as Company Group Chairman of LifeScan Inc., the blood glucose division of JNJ. Under Eric's leadership, LifeScan Global Diabetes franchise experienced rapid organic and inorganic growth, including the acquisition of Inverness Medical Technology's Diabetes Care Products business. His leadership helped transform LifeScan into a global organization with thousands of employees and billions in annual revenues.
After retiring from JNJ, Eric served as chairman for a number of medical device startup companies including chairman of Nfocus Neuromedical, Symetis SA and CeQur SA. Eric also served as an operating partner for Geneva based Endeavour Vision Growth, a medical device growth fund. In this newly-formed role at DarioHealth Corp., Eric will be responsible for building out an SAB with renowned physicians who both understand and champion the benefits of digital therapeutics in managing complex chronic conditions.
Eric and the future SAB members will work alongside Dario's research and development team and external partners to develop and implement the Company's strategic roadmap for Dario's technology platform. This includes expanding the company's offering to address additional chronic conditions and integrating additional technologies such as a continuous glucose monitor (CGM). Activities will also include the generation of additional data supporting the use of Dario's platform for managing chronic disease and acting as a reference resource for clients and potential clients in the business-to-business-to-consumer (B2B2C) channel. The primary objectives of this strategic initiative will be to help drive market awareness and the adoption of Dario's digital health solution.
"I am excited to join Dario as the company continues to refine and improve its digital therapeutics platform," stated Mr. Milledge. "I'm impressed with Dario's ability to engage patients and drive clinically meaningful improvements through better management of their chronic conditions. With additional resources and the execution of the company's strategic roadmap, I believe Dario will have a best-in-class platform that is unrivaled in the industry."
"We are very pleased that Eric is spearheading our effort to assemble a world-class SAB," commented Erez Raphael, Dario's CEO. "He brings significant experience and knowledge relevant to our industry, and a vast network of thought leaders across the diabetes treatment landscape. We believe Eric can help take our technology to the next level by attracting scientific and strategic business partners who will strengthen our platform and ultimately our reputation as a pioneer and leader in digital therapeutics. We believe that our leadership position will improve our ability to execute within the B2B2C channel, winning new accounts and further penetrating the significant opportunity that already exists within our current customer base."
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading, global digital therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, we empower individuals to make healthy adjustments to their daily lifestyle choices to improve their overall health. Our cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario is one of the highest-rated diabetes solutions in the market, and its user-centric MyDario™ mobile app is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new chronic conditions and geographic markets, using a performance-based approach to improve the health of users managing chronic disease. To learn more about DarioHealth and its digital health solutions, or for more information, visit http://mydario.investorroom.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue" are intended to identify forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the intended purpose and plans of the SAB, the belief that with additional resources and the execution of its strategic roadmap, it will have a best-in-class platform that is unrivaled in the industry, that the addition of Eric Milledge to the SAB can help take its technology to the next level by attracting scientific and strategic business partners who will strengthen its platform and ultimately its reputation as a pioneer and leader in digital therapeutics and the belief that its leadership position will improve its ability to execute within the B2B2C channel, winning new accounts and further penetrating the significant opportunity that already exists within its current customer base. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
DarioHealth Corporate Contact:
Content & Communications Manager
Investor Relations Contact:
SOURCE DarioHealth Corp.